Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9153460 | 1.00 | ALDH1A1 (0.62) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL15832673 | 0.92 | ALDH1A1 (0.55) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL10985089 | 0.91 | ALDH1A1 (0.72) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL1684895 | 0.91 | — | — | |
| SCHEMBL7034033 | 0.85 | SMN1; SMN2 (0.50) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL26614720 | 0.84 | TDP1 (0.48) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| Tert-Butyl Formate SCHEMBL27641788 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL12150634 | 0.83 | ALDH1A1 (0.53) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL26614927 | 0.83 | CYP1A2 (0.46) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL10531585 | 0.83 | TDP1 (0.46) | ALDH1A1POLBSMN1; SMN2HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189606-B1 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RES & DEV (IL) | 2007-08-15 | — | — | EP | claimed |
| EP-1194410-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2006-01-18 | — | — | EP | claimed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | claimed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | claimed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | claimed |
| JP-2003502405-A | — | — | 2003-01-21 | — | — | JP | claimed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | claimed |
| EP-3816164-B9 | ISOTHIAZOLO[5,4-D]PYRIMIDINE COMPOUND AS IRAK4 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2024-07-10 | — | — | EP | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4194441-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-0567126-A1 | Processing composition for silver halide photographic material and processing method using same | FUJI PHOTO FILM CO., LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-5147765-A | Desilvering; stability, discoloration inhibition | FUJI PHOTO FILM CO., LTD. (JP) | 1992-09-15 | — | — | US | disclosed |
| EP-0427204-A1 | Method for processing silver halide colour photographic materials | Fuji Photo Film Co., Ltd. (JP) | 1991-05-15 | — | — | EP | disclosed |
| US-4940793-A | Pharmacologically active piperazino derivatives | RAVIZZA S.P.A. (IT) | 1990-07-10 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
| EP-0171636-A1 | Pharmacologically active piperazino derivatives and the process for their preparation | RAVIZZA S.p.A. (IT) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | ALDH1A1 2458/4885POLB 2862/4885SMN1; SMN2 456/4885 |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ALDH1A1 977/4885POLB 4499/4885SMN1; SMN2 759/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | ALDH1A1 145/4885POLB 930/4885SMN1; SMN2 107/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ALDH1A1 1345/4885POLB 4392/4885SMN1; SMN2 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.